$EDIT

Gene-editing stocks fell Wednesday after Anthropic's AI model, Claude, identified a phage enzyme system with traits similar to CRISPR. CRISPR Therapeutics (CRSP) dropped 6%, Intellia (NTLA) 3%, Beam (BEAM) 6%, Prime Medicine (PRME) 12%, and Editas Medicine (EDIT) 8%. The discovery, called ART, links an RNA-to-DNA enzyme with repeating DNA and a mystery protein in bacteria-infecting viruses. CRISPR pioneer Feng Zhang called the finding intriguing but unproven.

Stifel upgraded Microsoft (MSFT) to Buy with a $575 price target, citing sustained revenue growth. Susquehanna upgraded RXO Inc. (RXO) to Neutral with a $19 target. JPMorgan upgraded Graphic Packaging (GPK) to Overweight with an $11.50 target. RBC upgraded Lakefront Biotherapeutics (LKFT) to Outperform with a $45 target. Guggenheim upgraded Editas Medicine (EDIT) to Buy with a $5 target. Wedbush downgraded Compass Therapeutics (CMPX) to Neutral with a $1 target.

Editas Medicine (EDIT) stock rose 7.2% in pre-market trading after Guggenheim upgraded it to Buy with a $5.00 price target, citing strong preclinical data for EDIT-401, its gene therapy for severe hypercholesterolemia. The move is company-specific, with broader markets trading lower. EDIT's 52-week range is $1.66 to $4.54.

Editas Medicine (NASDAQ:EDIT) aims to dose patients with its LDL gene-editing therapy, EDIT-401, in 2026, targeting a human-equivalent dose of 0.6 mg/kg. The Phase I/II study has two parts, with initial safety data expected in Q1 2025 and top-line data in 2027. The company has $212M in cash, expected to last until mid-2028, supporting the study's advancement. Editas estimates a U.S. market of 9-10M patients for its therapy.

Editas Medicine (EDIT) is advancing EDIT-401, a CRISPR therapy aiming for up to 90% LDL cholesterol reduction. First patient dosing is expected this year, with safety data in Q1 2027 and top-line results in 2027. The company has a strong cash position to support these milestones, according to its Cantor Fitzgerald conference presentation.

Editas Medicine (NASDAQ:EDIT) plans to start a Phase 1 trial for its CRISPR-based cholesterol therapy, EDIT-401, in Australia this year. The trial aims to treat patients with heterozygous familial hypercholesterolemia. Preclinical data suggests a 15% allele edit could significantly lower cholesterol. The company has $212 million in cash and expects its runway to extend into mid-2028.

Editas Medicine, Inc. (EDIT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Editas Medicine Announces Second Quarter 2026 Results and Business Updates EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoprotei

Editas Medicine, Inc. (EDIT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. edit-20260617 0001650664 FALSE 0001650664 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________________________________________________________________ FORM 8-K _____________________________________________

O'Neill Gilmore Neil (CEO) sold 15,380 shares of Editas Medicine, Inc. (EDIT) at $2.70 on 2026-06-03 under a Rule 10b5-1 trading plan.

Burkly Linda (EVP, CHIEF SCIENTIFIC OFFICER) sold 731 shares of Editas Medicine, Inc. (EDIT) at $2.70 on 2026-06-03 under a Rule 10b5-1 trading plan.